PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Files An 8-K Regulation FD Disclosure
Item7.01 Regulation FD Disclosure.
On April4, 2017, Pieris Pharmaceuticals, Inc. presented
IND-enabling data for PRS-343, a first-in-class 4-1BB/HER2
bispecific, in a poster session at the American Association for
Cancer Research conference (AACR) in Washington, D.C. The poster
is furnished as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated by reference herein.
Attached hereto as Exhibit 99.2 and incorporated by reference
herein is press release regarding the presentation at AACR.
The information set forth under this Item 7.01. Regulation FD
Disclosure, including the exhibits attached hereto, shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended, nor shall it be deemed incorporated by
reference into any filing under the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
reference in such filing.
Item9.01 Financial Statements and Exhibits
(d)Exhibits.
| 99.1 |
Industry Conference Presentation of Pieris Pharmaceuticals, Inc., dated April 2017. |
|
| 99.2 | Press Release dated April4, 2017. |
About PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS)
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate. PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Recent Trading Information
PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) closed its last trading session 00.00 at 2.57 with 171,350 shares trading hands.
